Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer

PURPOSE: Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients with colorectal cancer (CRC) and type II diabetes mellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Omari, Amal, Abdelkhaleq, Hadeel, Al-Hussaini, Maysa, Turfa, Rim, Awad, Nour, Hassan, Manal M., Alfaqih, Mahmoud A., Garrett, Christopher R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223523/
https://www.ncbi.nlm.nih.gov/pubmed/30084749
http://dx.doi.org/10.1200/JGO.18.00018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223523/
https://www.ncbi.nlm.nih.gov/pubmed/30084749
http://dx.doi.org/10.1200/JGO.18.00018

Ejemplares similares